The recent advancements in RNA modulators with multiple mechanisms of action (MOAs) has unlocked a plethora of new biotherapeutics to target previously undruggable pathways.
In addition to therapeutics that directly target RNA binding, there have also been recent advances in discovery of RNA epigenetics, splicing modulators and modulators of transcription/translation. RNA degradation by RiboTACs or RiboSNAPs is also opening significant innovative opportunities in this complex and expanding research area.
The SCI “New modalities” series comprises focussed in-person events and this year’s symposium brings together world-class scientists at the forefront of RNA research.
This event is for academic and industrial scientists interested in insights into the challenges posed and potential for RNA biotherapeutics to make a real-world impact, plus networking with active researchers in this space.
In addition to therapeutics that directly target RNA binding, there have also been recent advances in discovery of RNA epigenetics, splicing modulators and modulators of transcription/translation. RNA degradation by RiboTACs or RiboSNAPs is also opening significant innovative opportunities in this complex and expanding research area.
The SCI “New modalities” series comprises focussed in-person events and this year’s symposium brings together world-class scientists at the forefront of RNA research.
This event is for academic and industrial scientists interested in insights into the challenges posed and potential for RNA biotherapeutics to make a real-world impact, plus networking with active researchers in this space.
